Section Arrow
AGIO.NASDAQ
- Agios Pharmaceuticals
Quotes are at least 15-min delayed:2026/10/20 18:05 EDT
After Hours
Last
 36.09
-0.55 (-1.50%)
Bid
33.54
Ask
41.33
High 37.35 
Low 36.09 
Volume 129.10K 
Regular Hours (Closed)
Last
 36.64
+1.74 (+4.99%)
Day High 
37 
Prev. Close
34.9 
1-M High
35.36 
Volume 
1.52M 
Bid
33.54
Ask
41.33
Day Low
35.02 
Open
35.04 
1-M Low
29.67 
Market Cap 
2.08B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 31.78 
20-SMA 32.4 
50-SMA 33.11 
52-W High 46 
52-W Low 22.24 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.01/-4.20
Enterprise Value
2.11B
Balance Sheet
Book Value Per Share
17.19
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
54.03M
Operating Revenue Per Share
0.40
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
EYPTEyePoint Inc.0.4052-0.0348-7.91%-- 
After Hours 0.4182 +0.013 +3.21%
RXRXRecursion Pharmaceuticals3.66+0.05+1.39%-- 
After Hours 3.67 +0.01 +0.27%
MRNAModerna242.08+15.19+6.69%-- 
After Hours 241.61 -0.47 -0.19%
IBRXImmunityBio8.77+0.35+4.16%-- 
After Hours 8.73 -0.04 -0.46%
SLNSilence Therapeutics Plc19.61+0.03+0.15%-- 
After Hours 19.61 0 0.00%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.